FLB Stock Overview Provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Standard BioTools Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Standard BioTools Historical stock prices Current Share Price US$1.67 52 Week High US$2.68 52 Week Low US$1.27 Beta 1.57 1 Month Change -7.73% 3 Month Change 5.70% 1 Year Change -3.47% 3 Year Change -40.74% 5 Year Change -50.00% Change since IPO -85.49%
Recent News & Updates
Standard BioTools Inc. Announces SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine Jan 08 Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024
Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.073 loss per share (vs US$0.27 loss in 3Q 2023) Nov 01
Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
No longer forecast to breakeven Aug 02 See more updates
Standard BioTools Inc. Announces SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine Jan 08 Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024
Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.073 loss per share (vs US$0.27 loss in 3Q 2023) Nov 01
Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
No longer forecast to breakeven Aug 02
Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024 Aug 02
New major risk - Share price stability Aug 01
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.22 loss in 2Q 2023) Aug 01
Standard BioTools Inc. Announces Chief Financial Officer Changes Aug 01
High number of new and inexperienced directors Jul 25
Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Standard BioTools Inc., Annual General Meeting, Jun 27, 2024 May 24
Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024 May 10
Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 27 Standard BioTools Inc. Announces Operational Restructuring Plan Apr 26
Now 23% overvalued after recent price rise Apr 12
Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging Apr 09
Forecast to breakeven in 2026 Mar 03
New major risk - Financial position Mar 01
Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024 Mar 01
Full year 2023 earnings released: US$0.94 loss per share (vs US$2.43 loss in FY 2022) Feb 29
Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
New major risk - Revenue and earnings growth Jan 09
Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023 Jan 09 SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.
Third quarter 2023 earnings released: US$265 loss per share (vs US$0.37 loss in 3Q 2022) Nov 09
Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 26 SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 06
SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 05
Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.82 loss in 2Q 2022) Aug 09
Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
High number of new directors Jun 21
Senior VP & CFO recently bought €179k worth of stock May 23
Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System May 19 Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer
First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022) May 11
Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors May 05
Standard BioTools Inc. Provides Earnings Guidance for the Year 2023 Feb 16
Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021) Feb 16
Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023 Feb 01
Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer Jan 04
Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares. Nov 29
Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) Nov 10
Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform Oct 07
Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021) Aug 10
Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022 Aug 10
Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate Secretary Jul 09
Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global Operations Jun 29
Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value Index Jun 26
First quarter 2022 earnings released: US$0.99 loss per share (vs US$0.25 loss in 1Q 2021) May 07
Standard BioTools Inc., Annual General Meeting, Jun 15, 2022 May 02
Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 23
Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging Apr 12 Fluidigm Corporation Announces Board Changes
Fluidigm Corporation Announces Management Changes Mar 30
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19
Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.083 loss in 3Q 2020) Nov 09
Fluidigm Corporation Announces the Publication of New Data Further Validating the Potential of Its Mass Cytometry Technologies Sep 01
Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.18 loss in 2Q 2020) Aug 08 Fluidigm Corporation Revises Earnings Guidance for the Fiscal Year 2021
Fluidigm Corporation Announces Launch of CyTOF XT May 26
First quarter 2021 earnings released: US$0.25 loss per share (vs US$0.23 loss in 1Q 2020) May 08 Fluidigm Corporation Provides Revenue Guidance for the Second Quarter of 2021
Fluidigm Corporation Announces FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay Mar 03
Full year 2020 earnings released: US$0.74 loss per share (vs US$0.97 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28
Full year 2020 earnings released: US$0.74 loss per share (vs US$0.97 loss in FY 2019) Feb 13
Revenue misses expectations Feb 13
Fluidigm Corporation Announces Collaboration with Zhejiang Puluoting Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China Feb 11
New 90-day high: €5.95 Feb 11
Fluidigm Corporation Announces Fluidigm® Mass Cytometry Technology and the Maxpar® Direct™ Immune Profiling Assay™ Feb 10 Shareholder Returns FLB DE Life Sciences DE Market 7D 0.6% 4.5% 1.2% 1Y -3.5% 1.2% 10.1%
See full shareholder returns
Return vs Market: FLB underperformed the German Market which returned 9.4% over the past year.
Price Volatility Is FLB's price volatile compared to industry and market? FLB volatility FLB Average Weekly Movement 11.3% Life Sciences Industry Average Movement 7.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: FLB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: FLB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Show more Standard BioTools Inc. Fundamentals Summary How do Standard BioTools's earnings and revenue compare to its market cap? FLB fundamental statistics Market cap €632.37m Earnings (TTM ) -€165.60m Revenue (TTM ) €151.33m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) FLB income statement (TTM ) Revenue US$155.90m Cost of Revenue US$80.19m Gross Profit US$75.71m Other Expenses US$246.32m Earnings -US$170.60m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.46 Gross Margin 48.57% Net Profit Margin -109.43% Debt/Equity Ratio 11.3%
How did FLB perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/09 19:31 End of Day Share Price 2025/01/09 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Standard BioTools Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sung Ji Nam BTIG Bryan Brokmeier Cantor Fitzgerald & Co. Shawn Bevec Deutsche Bank
Show 10 more analysts 
